Status:
UNKNOWN
Outcomes of MF Patients Exposure to Ruxolitinib During Transplantation
Lead Sponsor:
xuna
Conditions:
Time of Hematopoietic Reconstruction
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Increasing experience of Ruxolitinib pre-allo SCT and data concerning Ruxolitinib during transplantation 1. Diagnosis MF(includ Post-ET,Post-PV,PMF,MDS/MPN with MF) 2. With at least two month Ruxolit...
Eligibility Criteria
Inclusion
- Age 18-60 years old, gender is not limited;
- Diagnosis MF(includ Post-ET,Post-PV,PMF) according to 2016 WHO
- With at least two month Ruxolitinib treatment before transplantation
- Informed consent of the patient or his legal representative
Exclusion
- HCT-CI score≥2
- Woman who is pregnant or nursing
- MPN Patients who have received allogeneic hematopoietic stem cell transplantation
Key Trial Info
Start Date :
April 20 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04526223
Start Date
April 20 2017
End Date
December 31 2022
Last Update
April 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NanfangH
Guangzhou, Guangdong, China, 510515